Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2019

Geoffrey W Coombs, Denise A Daley, Shakeel Mowlaboccus, Stanley Pang

# Abstract

From 1 January to 31 December 2019, thirty-nine institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2019 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the E. faecium isolates. Of the 1,361 unique episodes of bacteraemia investigated, 95.2% were caused by either E. faecalis (51.4%) or E. faecium (43.8%). Ampicillin resistance was not detected in E. faecalis but was detected in 91.1% of E. faecium. Vancomycin non-susceptibility was detected in 0.1% of E. faecalis and in 41.8% of E. faecium. Overall, 45.4% of E. faecium harboured vanA and/or vanB genes. For the vanA/vanB positive E. faecium isolates, 49.1% harboured vanA genes only and 50.6% vanB genes; 0.3% harboured both vanA and vanB genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is substantially higher than that seen in most European countries. E. faecium consisted of 78 multilocus sequence types (STs), of which 75.0% of isolates were classified into six major STs containing ten or more isolates. All major STs belong to clonal cluster (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. The predominant STs (ST1424, ST17, ST796, ST80, ST1421, and ST78) were found across most regions of Australia. The most prevalent clone was ST1424, which was identified in all regions except the Northern Territory and Western Australia. Overall, 51.4% of isolates belonging to the six predominant STs harboured vanA or vanB genes. In 2019, AESOP has shown that enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant vanA or vanB E. faecium which have limited treatment options.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveillance; Enterococcus faecium; Enterococcus faecalis; vancomycin-resistant enterococci (VRE); bacteraemia

# Background

Globally, Enterococcus is thought to account for approximately 10% of all bacteraemias, and in North America and Europe is the fourth and fifth leading cause of sepsis respectively.1,2 Although in the 1970s healthcare-associated enterococcal infections were primarily due to Enterococcus faecalis, there has been a steadily-increasing prevalence of E. faecium nosocomial infections.3–5 Worldwide, the increase in nosocomial E. faecium infections has primarily been due to the expansion of polyclonal hospital-adapted clonal complex (CC) 17 strains. While innately resistant to many classes of antibiotics, E. faecium has demonstrated a remarkable capacity to evolve new antimicrobial resistances. In 2009, the Infectious Diseases Society of America highlighted E. faecium as one of the key problem bacteria or ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens requiring new therapies.6

The Australian Group on Antimicrobial Resistance (AGAR) is a network of laboratories located across Australia that commenced surveillance of antimicrobial resistance in Enterococcus species in 1995.7 In 2011, AGAR initiated the Australian Enterococcal Sepsis Outcome Programme (AESOP).8,9 The objective of AESOP 2019 was to determine the proportion of E. faecalis and E. faecium bacteraemia isolates demonstrating antimicrobial resistance, with particular emphasis on:

* Assessing susceptibility to ampicillin;
* Assessing susceptibility to glycopeptides; and
* Ascertaining the molecular epidemiology of E. faecium.

# Methodology

## Participants

Thirty-nine laboratories from all Australian states and mainland territories.

## Collection period

From 1 January to 31 December 2019, the 39 laboratories collected all enterococcal species isolated from blood cultures. Enterococci with the same species and antimicrobial susceptibility profiles isolated from a patient’s blood culture within 14 days of the first positive culture were excluded. A new enterococcal sepsis episode in the same patient was recorded if it was confirmed by a further culture of blood taken more than 14 days after the initial positive culture. Data were collected on age, sex, dates of admission and discharge (if admitted), and mortality at seven and 30 days from date of blood culture collection. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated as ‘hospital-onset’ if the first positive blood culture(s) in an episode was collected > 48 hours after admission.

## Laboratory testing

Enterococcal isolates were identified to the species level by the participating laboratories using matrix-assisted laser desorption ionization, MALDI (MALDI Biotyper [Bruker Daltonics, Germany] or Vitek-MS® [bioMérieux, France]), or by the Vitek2® (bioMérieux). Antimicrobial susceptibility testing was performed using the Vitek2® (bioMérieux) or the Phoenix™ (Becton Dickinson, USA) automated microbiology systems according to the manufacturer’s instructions. Minimum inhibitory concentration (MIC) data and isolates were referred to the Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory at Murdoch University. Breakpoints as identified by the Clinical and Laboratory Standards Institute (CLSI)10 and European Committee on Antimicrobial Susceptibility Testing (EUCAST)11 were utilised for interpretation.Linezolid- and daptomycin-non-susceptible isolates and vancomycin-susceptible isolates which harboured vanA or vanB genes were retested by Etest® (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer. E. faecalis ATCC® 29212 was used as the control strain. Molecular testing was performed by whole genome sequencing (WGS) using the NextSeq® platform (Illumina, USA). Sequencing results were analysed using the Nullarbor pipeline.12

A chi-square test for comparison of two proportions was performed and 95% confidence intervals (95% CI) were determined using MedCalc for Windows, version 12.7 (MedCalc Software, Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

# Results

From 1 January to 31 December 2019, a total of 1,361 unique episodes of enterococcal bacteraemia were identified. Although nine Enterococcus species were identified, 51.4% of isolates (699) were E. faecalis and 43.8% (596 isolates) were E. faecium. The remaining 66 enterococci were identified either as E. casseliflavus (22 isolates), E. gallinarum (21 isolates), E. avium (13 isolates), E. hirae (3 isolates), E. raffinosus (3 isolates), *E. durans* (3 isolates), or E. thailandicus (1 isolate).

A significant difference was seen in patient sex (p < 0.0001), with 890 patients (65.4%) male (95% CI: 62.8–67.9). The average age of patients was 64 years, ranging from 0 to 102 years, with a median age of 69 years. The majority of episodes, 52.9% (720/1,361), were community-onset (95% CI: 50.2–55.6). However, a significant difference (p < 0.0001) in place of onset was seen between E. faecium and E. faecalis, with only 30.2% (95% CI: 26.5–34.0) of E. faecium episodes being community-onset versus 69.7% (95% CI: 66.1–73.1) for E. faecalis. All-cause mortality at 30 days, where data were known, was 20.6% (95% CI: 18.2–23.1). There was a significant difference (p < 0.0001) in mortality between E. faecalis and E. faecium episodes (13.7% vs 26.4% respectively), but not between vancomycin-susceptible and vancomycin-non-susceptible E. faecium episodes (24.0% vs 30.9% respectively, p = 0.17).

## *E. faecalis* phenotypic susceptibility results

Apart from erythromycin, tetracycline, ciprofloxacin and high-level gentamicin, acquired resistance was rare amongst E. faecalis (Table 1). One isolate with a vancomycin MIC of 16 mg/L was considered intermediate by CLSI and resistant by EUCAST interpretive criteria. One isolate with an ampicillin MIC of 8 mg/L was considered susceptible by CLSI criteria and intermediate by EUCAST criteria; van genes were not detected in this isolate. A total of 43 E. faecalis isolates (6.2%) were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). However by Etest®, 42 of the 43 isolates had a linezolid MIC of ≤ 2 mg/L and were therefore considered linezolid susceptible. The remaining isolate with an MIC of 4 mg/L, although intermediate by CLSI criteria, was considered susceptible by EUCAST criteria. One isolate was initially reported as daptomycin resistant (≥ 8 mg/L) by CLSI criteria, however this isolate was unavailable for confirmation by Etest®.

Table 1: The number and proportion of *E. faecalis* non-susceptible to ampicillin and the non-β-lactam antimicrobials, Australia, 2019

| Antimicrobial | Tested | Breakpoint Guideline | Breakpoint (mg/L)a | | | Susceptible | Intermediate | Resistant |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| S | I | R | N (%) | N (%) | N (%) |
| Ampicillin | 698 | CLSI | ≤ 8 |  | ≥ 16 | 698 (100) |  | 0 (0) |
| EUCAST | ≤ 4 | 8 | > 8 | 697 (99.9) | 1 (0.1) | 0 (0) |
| Vancomycin | 698 | CLSI | ≤ 4 | 8–16 | ≥ 32 | 697 (99.9) | 1 (0.1) | 0 (0) |
| EUCAST | ≤ 4 |  | > 4 | 697 (99.9) |  | 1 (0.1) |
| Erythromycin | 549 | CLSI | ≤ 0.5 | 1–4 | ≥ 8 | 45 (8.2) | 276 (50.3) | 228 (41.5) |
| Tetracycline/doxycycline | 425 | CLSI | ≤ 4 | 8 | ≥ 16 | 141 (33.2) |  | 284 (66.8) |
| Ciprofloxacin | 429 | CLSI | ≤ 1 | 2 | ≥ 4 | 379 (88.3) | 14 (3.3) | 36 (8.4) |
| Daptomycin | 679 | CLSI | ≤ 2 | 4 | ≥ 8 | 579 (77.6) | 151 (22.2) | 1 (0.1) |
| Teicoplanin | 698 | CLSI | ≤ 8 | 16 | ≥ 32 | 698 (100) | 0 (0) | 0 (0) |
| EUCAST | ≤ 2 |  | > 2 | 696 (99.7) |  | 2 (0.3) |
| Linezolid | 698 | CLSI | ≤ 2 | 4 | ≥ 8 | 694 (99.4) | 4 (0.6) | 0 (0) |
| EUCAST | ≤ 4 |  | > 4 | 698 (100) | 0 (0) | 0 (0) |
| Nitrofurantoin | 693 | CLSI | ≤ 32 | 64 | ≥ 128 | 683 (98.6) | 9 (1.3) | 1 (0.1) |
| High-level gentamicin | 510 | EUCAST | < 128 |  | ≥ 128 | 423 (82.9) |  | 87 (17.1) |

a S: susceptible; I: intermediate; R: resistant

## **E. faecium **phenotypic susceptibility results****

The majority of E. faecium isolates were non-susceptible to multiple antimicrobials including ampicillin, erythromycin, tetracycline, ciprofloxacin, nitrofurantoin and high-level gentamicin (Table 2). Overall, 249 isolates (41.8%) were phenotypically vancomycin non-susceptible (MIC > 4 mg/L). One hundred and seven (18%) and 114 (19.2%) isolates were teicoplanin non-susceptible by CLSI and EUCAST criteria respectively. Nineteen (3.2%) isolates were initially reported as linezolid non-susceptible (CLSI breakpoint > 2 mg/L). However, by Etest®, 15 of the 16 isolates had linezolid MICs of ≤ 2 mg/L and therefore were considered susceptible. One isolate with an MIC of 3.0 mg/L by Etest®, although intermediate by CLSI criteria, was considered susceptible by EUCAST criteria.

Table 2: The number and proportion of *E. faecium* non-susceptible to ampicillin and the non-β-lactam antimicrobials, Australia, 2019

| Antimicrobial | Tested | Breakpoint Guideline | Breakpoint (mg/L)a | | | Susceptible | Intermediate | Resistant |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| S | I | R | % | % | % |
| Ampicillin | 595 | CLSI | ≤ 8 |  | ≥ 16 | 8.9 |  | 91.1 |
| EUCAST | ≤ 4 | 8 | > 8 | 8.7 | 0.2 | 91.1 |
| Vancomycin | 596 | CLSI | ≤ 4 | 8–16 | ≥ 32 | 58.2 | 0.7 | 41.1 |
| EUCAST | ≤ 4 |  | > 4 | 58.4 |  | 41.6 |
| Erythromycin | 500 | CLSI | ≤ 0.5 | 1–4 | ≥ 8 | 5.4 | 10.2 | 84.4 |
| Tetracycline/doxycycline | 442 | CLSI | ≤ 4 | 8 | ≥ 16 | 36.9 | 0.0 | 63.1 |
| Ciprofloxacin | 386 | CLSI | ≤ 1 | 2 | ≥ 4 | 7.5 | 3.1 | 89.4 |
| Daptomycin | 96 | CLSI |  | 4b | ≥ 8 |  | 99.0 | 1.0 |
| Teicoplanin | 594 | CLSI | ≤ 8 | 16 | ≥ 32 | 82.0 | 1.3 | 16.7 |
| EUCAST | ≤ 2 |  | > 2 | 81.5 |  | 19.2 |
| Linezolid | 594 | CLSI | ≤ 2 | 4 | ≥ 8 | 99.6 | 0.2 | 0.2 |
| EUCAST | ≤ 4 |  | > 4 | 99.8 |  | 0.2 |
| Nitrofurantoin | 513 | CLSI | ≤ 32 | 64 | ≥ 128 | 16.4 | 25.3 | 58.3 |
| High-level gentamicin | 427 | EUCAST | < 128 |  | ≥ 128 | 54.6 |  | 45.4 |

a S: susceptible; I: intermediate; R: resistant

b Susceptible dose dependant

## Genotypic vancomycin susceptibility results

For 382 (54.7%) of the 699 E. faecalis isolates, vanA/vanB PCR results were available; vanA genes were not detected. One isolate which had a vancomycin MIC of 2 mg/L harboured vanB genes. WGS was not performed on the E. faecalis isolates.

The presence of vanA/vanB genes was determined by polymerase chain reaction (PCR) or WGS on 588 (98.7%) of the 596 E. faecium isolates. Overall, 267 of the 588 isolates (45.4%) harboured a vanA and/or vanB gene. One hundred and 20 of the vancomycin-non-susceptible E. faecium isolates harboured vanA (Vitek® vancomycin MIC > 4 mg/L). A further 128 E. faecium vancomycin non-susceptible isolates harboured vanB. One isolate harboured both vanA and vanB genes. vanA or vanB genes were detected in eighteen vancomycin-susceptible E. faecium isolates. Eleven isolates harboured vanA. These isolates had Vitek® vancomycin MICs ≤ 4.0mg/L; 2.0 mg/L [5 isolates], 1.0 mg/L [5 isolates] and ≤ 0.5 mg/L [1 isolate], and teicoplanin 2.0 mg/L (1 isolate] and ≤ 1.0 mg/L [10 isolates]. Seven isolates harboured vanB (Vitek® vancomycin MIC 2.0 mg/L [7 isolates]).

## *E. faecium* molecular epidemiology

Of the 596 episodes, 568 E. faecium isolates (95.3%) were available for typing by WGS. The 568 isolates were classified into 78 sequence types (STs), including six STs with 10 or more isolates (Table 3). Of the 72 STs with < 10 isolates, 49 had only one isolate. Overall, 432 (75.0%) of the 568 isolates were grouped into the six major STs. Using eBURST, all major STs were grouped into CC 17.

Table 3: The number and proportion of major *Enterococcus faecium* sequence types, Australia, 2019, by regiona

| ST | ACT | | NSW | | NT | | Qld | | SA | | Tas | | Vic | | WA | | Aus | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| ST1424 | 3 | 15.8 | 80 | 41.5 |  |  | 3 | 5.0 | 2 | 4.8 | 16 | 64.0 | 29 | 17.9 |  |  | 133 | 23.4 |
| ST17 |  |  | 16 | 8.3 | 1 | 7.7 | 33 | 55.0 | 14 | 33.3 | 1 | 4.0 | 11 | 6.8 | 26 | 48.1 | 102 | 18.0 |
| ST796 |  |  | 4 | 2.1 |  |  | 1 | 1.7 | 2 | 4.8 | 4 | 16.0 | 62 | 38.3 | 1 | 1.9 | 74 | 13.0 |
| ST80 | 5 | 26.3 | 17 | 8.8 | 1 | 7.7 | 3 | 5.0 | 5 | 11.9 |  |  | 9 | 5.6 | 12 | 22.2 | 52 | 9.2 |
| ST1421 | 4 | 21.1 | 37 | 19.2 |  |  | 2 | 3.3 |  |  |  |  | 6 | 3.7 |  |  | 49 | 8.6 |
| ST78 | 1 | 5.3 | 8 | 4.1 |  |  | 4 | 6.7 |  |  |  |  | 9 | 5.6 |  |  | 22 | 3.9 |
| Other | 6 | 31.6 | 31 | 16.1 | 11 | 84.6 | 14 | 23.3 | 19 | 45.2 | 4 | 16.0 | 36 | 22.2 | 15 | 27.8 | 136 | 23.9 |
| **Total** | **19** | **100** | **193** | **100** | **13** | **100** | **60** | **100** | **42** | **100** | **25** | **100** | **162** | **100** | **54** | **100** | **568** | **100** |

a ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

Geographical distribution of the STs varied (Table 3). For the six major STs, ST1424 (133 isolates) was identified in all regions except the Northern Territory and Western Australia; ST17 (102 isolates) was identified in all regions except the Australian Capital Territory; ST796 (74 isolates) in all regions except the Australian Capital Territory and the Northern Territory; ST80 (52 isolates) in all regions except Tasmania; and ST1421 (49 isolates) and ST78 (22 isolates) were each found in all regions except the Northern Territory, South Australia, Tasmania and Western Australia.

In four major STs (118 isolates: ST1424, ST17, ST80 and ST1421), vanA was detected; vanB was detected in five major STs (103 isolates: ST1424, ST17, ST796, ST80, and ST78) (Table 4). One ST796 isolate harboured both vanA and vanB genes. Eight minor STs (9 isolates) harboured vanA genes and seven minor STs (25 isolates) harboured vanB genes.

Table 4: The number and proportion of major *Enterococcus faecium* sequence types harbouring vanA/vanB genes, Australia, 2019

| ST | n | vanA | | vanB | | vanA and vanB | | Not Detected | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| n | % | n | % | n | % | n | % |
| ST1424 | 133 | 72 | 56.7 | 2 | 1.6 |  |  | 59 | 18.9 |
| ST17 | 102 | 3 | 2.4 | 4 | 3.1 |  |  | 95 | 30.4 |
| ST796 | 74 |  |  | 71 | 55.5 | 1 | 100 | 2 | 0.6 |
| ST80 | 52 | 6 | 4.7 | 5 | 3.9 |  |  | 41 | 13.1 |
| ST1421 | 49 | 37 | 29.1 |  |  |  |  | 12 | 3.8 |
| ST78 | 22 |  |  | 21 | 16.4 |  |  | 1 | 0.3 |
| Other | 136 | 9 | 7.1 | 25 | 19.5 |  |  | 102 | 32.7 |
| **Total** | **568** | **127** | **100** | **128** | **100** | **1** | **100** | **312** | **100** |

# Discussion

Enterococci are intrinsically resistant to a broad range of antimicrobials including the cephalosporins and sulphonamides. By their ability to acquire additional resistance through the transfer of plasmids and transposons, and to disseminate easily in the hospital environment, enterococci have become difficult to treat and provide major infection control challenges.

As the AGAR programs are similar to those conducted in Europe, comparison of Australian antimicrobial resistance data with other countries is possible.

In the 2018 European Centre for Disease Prevention and Control (ECDC) enterococci surveillance program, the European Union/European Economic Area (EU/EEA) population-weighted mean percentage of E. faecium resistant to vancomycin was 17.3% (95% CI: 17–18), which represents a significant increase from 2014 when the percentage was 10.4%. The national percentages ranged from 0.0% in Iceland (95% CI: 0–21), Luxembourg (95% CI: 0–12), and Slovenia (95% CI: 0–3) to 59.1% (95% CI: 43–74) in Cyprus.13

In AESOP 2019, 43.8% of enterococcal bacteraemia were due to E. faecium, of which 41.8% (95% CI: (37.8-45.9) were phenotypically vancomycin non-susceptible by Vitek2® or Phoenix™. However, 45.4% of E. faecium isolates tested (265/588) harboured vanA/vanB genes, of which 49.1% were vanA. Overall, 22.3% (131/588) of E. faecium isolates harboured the vanA gene. There has been a significant increase in vanA E. faecium in Australia over the AGAR surveys 2013 to 2018,from 6% in 2013 to 26.1% in 2018.14–19 The majority of E. faecium isolates were also non-susceptible to multiple antimicrobials, including ampicillin, erythromycin, tetracycline, ciprofloxacin and high-level gentamicin. The AESOP surveys confirm the incidence of vancomycin-resistant E. faecium bacteraemia in Australia is a significant problem.

Seven of the 135 vanB E. faecium isolates (6.6%) and eleven (8.3%) of the 131 vanA E. faecium isolates had a vancomycin MIC at or below the CLSI and the EUCAST susceptible breakpoint (≤ 4 mg/L), and therefore would not have been identified using routine phenotypic antimicrobial susceptibility methods.

By WGS, E. faecium was shown to be very polyclonal, consistent with the known plasticity of the enterococcal genome. The six major E. faecium STs form part of CC 17, a global hospital-derived lineage that has successfully adapted to hospital environments. The CC 17 lineage is characteristically ampicillin and quinolone resistant, and subsequent acquisition of vanA- or vanB-containing transposons by horizontal transfer in CC 17 clones has resulted in VRE with pandemic potential.

In AESOP 2019, six E. faecium STs predominated: ST1424 (of which 54.1% of isolates harboured vanA genes and 1.5% vanB genes); ST17 (2.9% vanA, 3.9% vanB); ST796 (0% vanA, 95.9% vanB, 1.4% vanA and vanB); ST80 (11.5% vanA, 9.6% vanB); ST1421 (75.5% vanA, 0% vanB); and ST78 (0% vanA, 95.5% vanB).

# Conclusions

The AESOP 2019 study has shown that, although still predominately caused by E. faecalis, enterococcal bacteraemia in Australia is frequently caused by ampicillin-resistant, high-level gentamicin-resistant vancomycin-resistant E. faecium. Furthermore, the percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is significantly higher than that seen in almost all European countries. While the vanB operon was the predominant genotype in Australia, in 2019 49.1% of E. faecium harboured the vanA gene. In addition to being a significant cause of healthcare-associated sepsis, the emergence of multiple multi-resistant hospital-adapted E. faecium strains has become a major infection control issue in Australian hospitals. Ongoing studies on the enterococcal genome will contribute to our understanding of the rapid and ongoing evolution of enterococci in the hospital environment and will assist in preventing their nosocomial transmission.

# Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Health Care.

Members of the AGAR in 2019 were:

## Australian Capital Territory

Peter Collignon and Susan Bradbury, The Canberra Hospital

## New South Wales

Thomas Gottlieb and John Huynh, Concord Hospital

James Branley and Linda Douglass, Nepean Hospital

Angela Wong, Royal North Shore Hospital

Sebastiaan van Hal and Alicia Beukers, Royal Prince Alfred Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Rod Givney and Bree Harris, John Hunter Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

Jock Harkness and David Lorenz, St Vincent’s Hospital

Monica Lahra and Peter Huntington, Sydney Children’s Hospital

Michael Maley and Helen Ziochos, Liverpool Hospital

## Northern Territory

Rob Baird and Jann Hennessy, Royal Darwin Hospital

James McLeod, Alice Springs Hospital

## Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland,Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory, Royal Brisbane and Women’s Hospital

Petra Derrington and Cheryl Curtis, Pathology Queensland, Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology Queensland, Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland, Princess Alexandra Hospital

Jennifer Robson and Georgia Peachey, Sullivan Nicolaides Pathology, Greenslopes Hospital

Clare Nourse, Queensland Children’s Hospital

## South Australia

Kelly Papanaoum and Xiao Ming Chen, SA Pathology, Flinders Medical Centre

Morgyn Warner and Kija Smith, SA Pathology, Royal Adelaide Hospital and Women’s and Children’s Hospital

## Tasmania

Louise Cooley and David Jones, Royal Hobart Hospital

Pankaja Kalukottege and Kathy Wilcox, Launceston General Hospital

## Victoria

Denis Spelman and Chris Lee, The Alfred Hospital

Marcel Leroi and Elizabeth Grabsch, Austin Health

Tony Korman and Despina Kotsanas, Monash Medical Centre, Monash Children’s Hospital and Dandenong Hospital

Andrew Daley and Gena Gonis, Royal Women’s and Children’s Hospital

Mary Jo Waters and Lisa Brenton, St Vincent’s Hospital

## Western Australia

David McGechie and Denise Daley, PathWest Laboratory Medicine, WA Fiona Stanley Hospital

Ronan Murray and Jacinta Bowman, PathWest Laboratory Medicine, WA Sir Charles Gairdner Hospital

Michael Leung, PathWest Laboratory Medicine, Northwest WA

Owen Robinson and Geoffrey Coombs, PathWest Laboratory Medicine, WA Royal Perth Hospital

Sudha Pottumarthy-Boddu and Jacqueline Schuster, Australian Clinical Laboratories, St John of God Hospital, Murdoch

Shalinie Perera and Ian Meyer, Western Diagnostic Pathology, Joondalup Hospital

Christopher Blyth, Perth Children’s Hospital

# Author Details

Prof Geoffrey W Coombs,1,2

Ms Denise A Daley,2,3

Dr Shakeel Mowlaboccus,1

Dr Stanley Pang,1,2

on behalf of the Australian Group on Antimicrobial Resistance

1. Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
2. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding Author

Prof Geoffrey Coombs

Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: g.coombs@murdoch.edu.au

# References

1. Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51.
2. Deshpande LM, Fritsche TR, Moet Gj, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70.
3. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65.
4. Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother. 2003;51(2):323–31.
5. Treitman AN, Yarnold PR, Warren J, Noskin GA. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol. 2005;43(1):462–3.
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
7. Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC for the Australian Group on Antimicrobial Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.
8. Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5.
9. Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52(3):897–905.
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne, PA: CLSI; 2020.
11. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. Basel: EUCAST; 2020. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\_files/Breakpoint\_tables/v\_10.0\_Breakpoint\_Tables.pdf.
12. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed: 03 Jun 2016.] Available from: https://github.com/tseemann/nullarbor .
13. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. [Internet.] Solna: ECDC; 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018.
14. Coombs GW, Pearson JC, Daly DA, Le T, Robinson OJ, Gottlieb T et al. Australian Enterococcal Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E320–6.
15. Coombs GW, Daley DA, Lee YT, Pang S, Pearson JC, Robinson JO, Johnson PD et al. Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014. Commun Dis Intell Q Rep. 2016;40(2):E236–43.
16. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) annual report 2015. Commun Dis Intell(2018). 2018;42. pii: S2209-6051(18)00015-5.
17. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2016. Commun Dis Intell(2018). 2018;42. pii: S2209-6051(18)00020-9.
18. Coombs GW, Daley DA, Lee YT, Pang S on behalf of the Australian Group on Antimicrobial Resistance (AGAR). Australian Enterococcal Sepsis Outcome Programme (AESOP) annual peport 2017. Commun Dis Intell (2018). 2019;43. doi: http://doi.org/10.33321/cdi.2019.43.42.
19. Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) annual report 2018. Commun Dis Intell (2018). 2020;44. doi: http://doi.org/10.33321/cdi.2020.44.19.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Tanja Farmer

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:   
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>